Autobio Diagnostics Co., Ltd.
603658
Kedudukan dalam Saham
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Harga Saham
$5.15
Disegerakkan terakhir: 2026-10-22
Modal Pasaran
$2.94B
Perubahan (1 hari)
0.97%
Perubahan (1 tahun)
-5.80%
Negara
CN
Perdagangan Autobio Diagnostics Co., Ltd. (603658)
Kategori
Healthcare
Pendapatan untuk Autobio Diagnostics Co., Ltd. (603658)
Pendapatan pada Jun 2026 TTM: $169.22M
Menurut laporan kewangan terkini Autobio Diagnostics Co., Ltd., pendapatan semasa syarikat ialah $169.22M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $176.60M, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $192.49M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Autobio Diagnostics Co., Ltd. dari 2011 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $169.22M | -3.17% |
| 2025 | $174.77M | -1.04% |
| 2024 | $176.60M | -8.25% |
| 2023 | $192.49M | 2.63% |
| 2022 | $187.55M | 11.87% |
| 2021 | $167.65M | 29.68% |
| 2020 | $129.28M | 1.63% |
| 2019 | $127.20M | 33.67% |
| 2018 | $95.16M | 20.21% |
| 2017 | $79.16M | 34.78% |
| 2016 | $58.73M | 17.42% |
| 2015 | $50.02M | 28.06% |
| 2014 | $39.06M | 63.96% |
| 2013 | $23.82M | 27.82% |
| 2012 | $18.64M | 63.64% |
| 2011 | $11.39M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $7.87B | 4,550.10% |
US
|
|
| $4.82B | 2,747.14% |
US
|
|
| $-252.70M | -249.33% |
US
|
|
| $4.12B | 2,335.02% |
CN
|
|
| $1.66B | 879.78% |
US
|
